Clinical Trials Directory

Trials / Terminated

TerminatedNCT01374633

Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients

Effect on Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Main purpose of the study is to evaluate the effect of sevoflurane on intra cranial pressure (ICP) after traumatic brain injury. Patients admitted for traumatic brain injury equipped with ICP measurement will be sedated with sevoflurane via the Anaconda device during 12 hours. Sedation will be controlled with BIS.

Detailed description

Sedation is most of the time required for ICP management after traumatic brain injury. Sevoflurane, an inhaled anaesthetic drug is commonly used in operatory room. Thanks to a new device, the Anaconda, it now can be applied to intensive care patients. His advantages a rapid elimination after administration stops, which can allow an early neurologic evaluation, very important for traumatic brain injury patients.We will study the effect of sevoflurane administration on ICP of TBI patients. Patients admitted for severe TBI (Glasgow come scale \< 8), equipped with ICP sensor, elder than 18 years old will be include. A sedation with sevoflurane will be administrated during 12 hours instead of classical intra venous sedation with midazolam, depending on BIS score. ICP evolution will be characterised in success if \< 30 mmHg or failure if ≥ 30 mmHg.6 patients will be included for the first phase. The study will be stopped if the failures are ≥ 2. Otherwise, 27 patients will be included. Study will be stopped if failures number ≥ 5 before the end if the inclusion period.

Conditions

Interventions

TypeNameDescription
DRUG1: SevofluraneMean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."

Timeline

Start date
2011-12-01
Primary completion
2013-03-01
Completion
2013-03-01
First posted
2011-06-16
Last updated
2015-03-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01374633. Inclusion in this directory is not an endorsement.